deltatrials
Completed PHASE1/PHASE2 NCT00003105

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Phase I/II Trial of Sequential Doxorubicin/Gemcitabine (AG) and Ifosfamide, Paclitaxel, and Cisplatin (ITP) Chemotherapy (AG-ITP) in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Bladder Cancer Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions cisplatin doxorubicin hydrochloride filgrastim gemcitabine hydrochloride ifosfamide paclitaxel
Updated 5 times since 2017 Last updated: Jul 2, 2013 Started: Sep 30, 1997 Primary completion: Aug 31, 2004 Completion: Aug 31, 2004

This PHASE1/PHASE2 trial investigates Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Sep 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States